Alterity Therapeutics Ltd - Asset Resilience Ratio
Alterity Therapeutics Ltd (ATH) has an Asset Resilience Ratio of 86.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Alterity Therapeutics Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Alterity Therapeutics Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Alterity Therapeutics Ltd total assets.
Liquid Assets Composition Over Time
This chart breaks down Alterity Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ATH long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$49.20 Million | 86.44% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$49.20 Million | 86.44% |
Asset Resilience Insights
- Very High Liquidity: Alterity Therapeutics Ltd maintains exceptional liquid asset reserves at 86.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Alterity Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Alterity Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Upstream Bio, Inc.
NASDAQ:UPB |
Biotechnology | 64.70% |
Annual Asset Resilience Ratio for Alterity Therapeutics Ltd (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Alterity Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 16.30% | AU$7.50 Million ≈ $5.31 Million |
AU$46.03 Million ≈ $32.57 Million |
-- |
| 2024-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$19.22 Million ≈ $13.60 Million |
-- |
| 2022-06-30 | 84.15% | AU$34.81 Million ≈ $24.63 Million |
AU$41.36 Million ≈ $29.27 Million |
+0.44pp |
| 2021-06-30 | 83.71% | AU$28.12 Million ≈ $19.89 Million |
AU$33.59 Million ≈ $23.76 Million |
+82.26pp |
| 2020-06-30 | 1.45% | AU$192.71K ≈ $136.35K |
AU$13.30 Million ≈ $9.41 Million |
-70.88pp |
| 2019-06-30 | 72.33% | AU$14.40 Million ≈ $10.19 Million |
AU$19.91 Million ≈ $14.09 Million |
-9.09pp |
| 2018-06-30 | 81.41% | AU$15.25 Million ≈ $10.79 Million |
AU$18.73 Million ≈ $13.25 Million |
-5.33pp |
| 2017-06-30 | 86.74% | AU$21.93 Million ≈ $15.52 Million |
AU$25.28 Million ≈ $17.89 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$33.73 Million ≈ $23.86 Million |
-- |
| 2015-06-30 | 0.36% | AU$152.60K ≈ $107.98K |
AU$41.83 Million ≈ $29.60 Million |
-0.23pp |
| 2007-06-30 | 0.59% | AU$45.63K ≈ $32.28K |
AU$7.72 Million ≈ $5.46 Million |
+0.18pp |
| 2006-06-30 | 0.41% | AU$42.40K ≈ $30.00K |
AU$10.43 Million ≈ $7.38 Million |
-- |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more